Maze Raises $190M, Gears Up for First Clinical Testing of MZE001

Maze Raises $190M, Gears Up for First Clinical Testing of MZE001

315966

Maze Raises $190M, Gears Up for First Clinical Testing of MZE001

Maze Therapeutics has announced its plans to begin clinical testing of MZE001, its lead candidate therapy for Pompe disease, in the first half of this year. The California-based precision medicine company raised $190 million in financing — led by Matrix Capital Management — to support the development of MZE001 and other projects. “As we transition to a clinical-stage company, we believe this financing provides important resources to advance our pipeline and to uncover new genetic…

You must be logged in to read/download the full post.